Kwang Dong Pharmaceutical Co., Ltd. completed the acquisition of 55.98% stake in Korea ePlatform Ltd. from Kolon Global Corporation and other sellers.
March 17, 2015 at 12:00 am EDT
Share
Kwang Dong Pharmaceutical Co., Ltd. (KOSE:A009290) agreed to acquire 55.98% stake in Korea ePlatform Ltd. from Kolon Global Corporation (KOSE:A003070), Woo-Sok Lee and other sellers for KRW 40.7 billion on February 16, 2015. Under the transaction, Kwang Dong will acquire approximately 4.11 million shares of Korea ePlatform. Kolon will sell 3.83 million shares. Board of Directors of Kwang Dong Pharmaceutical Co., Ltd. and Kolon Global Corporation made a resolution in favor of the transaction on February 16, 2015. The transaction is expected to close on March 24, 2015. Samjong KPMG Advisory Inc. acted as financial advisor for Kwang Dong Pharmaceutical Co., Ltd.
Kwang Dong Pharmaceutical Co., Ltd. (KOSE:A009290) completed the acquisition of 55.98% stake in Korea ePlatform Ltd. from Kolon Global Corporation (KOSE:A003070), Woo-Sok Lee and other sellers on March 17, 2015.
Kwangdong Pharmaceutical Co Ltd is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Company operates its business through five segments. The Mineral Water Business segment supplies drinking spring water under Samdasoo brand. The Distribution Business segment distributes health drinks under brand names of Vita500 and Corn Silk Tea. The Pharmacy Business segment provides Chinese prescription cold medicines, hypertension medicines, cerebral apoplexy medicines and health drinks. The Hospital Business segment offers anticancer agents, blood vessel adjuvants, vitamin D injections and others. The Other segment provides products which not covered by Pharmacy, Hospital and Distribution segments.
KWANG DONG PHARMACEUTICAL CO., LTD. 
